Basal cell carcinoma: Management of advanced or metastatic cancer with checkpoint inhibitors and concurrent paradoxical development of new superficial tumors - 14/04/20
Doi : 10.1016/j.jaad.2020.02.052
Philip R. Cohen, MD a, b, c, d, ⁎ 
, Razelle Kurzrock, MD e, f
, Razelle Kurzrock, MD e, f a San Diego Family Dermatology, National City, California
b Touro University California College of Osteopathic Medicine, Vallejo, California
c Scripps Family Medicine Residency, Scripps Mercy Hospital Chula Vista, Chula Vista, California
d Family Medicine Residency, Family Health Centers of San Diego, San Diego, California
e Department of Medicine, Division of Hematology/Oncology, University of California San Diego, La Jolla, California
f Center of Personalized Cancer Therapy, University of California San Diego, La Jolla, California
∗Reprint requests: Philip R. Cohen, MD, 10991 Twinleaf Ct, San Diego, CA 92131-364310991 Twinleaf CtSan DiegoCA92131-3643
En prensa. Pruebas corregidas por el autor.
Disponible en línea desde el Tuesday 14 April 2020
El texto completo de este artículo está disponible en PDF.
| Funding sources: Supported in part by the Joan and Irwin Jacobs Fund and by National Cancer Institute grant P30 CA016672 (to Dr Kurzrock). |
|
| Disclosure: Dr Kurzrock has received research funding from Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine, Konica Minolta, Grifols, and Guardant Health; consultant fees from Merck, Pfizer, Roche, X-Biotech, and Actuate Therapeutics; and speaker fees from Roche; holds an ownership interest in CureMatch, Inc; and serves on the Board of CureMatch and CureMetrix, Inc. Dr Cohen has no conflicts of interest to declare. |
|
| IRB approval status: Not applicable. |
© 2020
American Academy of Dermatology, Inc.. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?